Protocol Ledger

NCT05768503 · Phase III · RECRUITING

Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC

Interventional Phase III clinical trial protocol NCT05768503 sponsored by Sun Yat-sen University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-01 Enrollment: 176 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05768503
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)176 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05768503
Protocol FieldVerified Registry Value
NCT IdentifierNCT05768503
Consolidated Lead SponsorSun Yat-sen University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment176 participants (ESTIMATED)
Registered Start Date2023-03-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI